Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
45.02
-0.06 (-0.13%)
Apr 24, 2026, 10:33 AM EDT - Market open
Corcept Therapeutics Employees
Corcept Therapeutics had 730 employees as of December 31, 2025. The number of employees increased by 230 or 46.00% compared to the previous year.
Employees
730
Change (1Y)
230
Growth (1Y)
46.00%
Revenue / Employee
$1,043,023
Profits / Employee
$134,481
Market Cap
4.83B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 730 | 230 | 46.00% | 730 | 0 |
| Dec 31, 2024 | 500 | 148 | 42.05% | 500 | 0 |
| Dec 31, 2023 | 352 | 53 | 17.73% | 352 | 0 |
| Dec 31, 2022 | 299 | 61 | 25.63% | 299 | 0 |
| Dec 31, 2021 | 238 | 2 | 0.85% | 238 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Apellis Pharmaceuticals | 739 |
| Amicus Therapeutics | 511 |
| TG Therapeutics | 399 |
| CRISPR Therapeutics AG | 393 |
| Mirum Pharmaceuticals | 372 |
| Xenon Pharmaceuticals | 370 |
| Scholar Rock Holding | 289 |
CORT News
- 18 hours ago - Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 2 days ago - Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026 - Business Wire
- 3 days ago - CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Corcept Therapeutics Incorporated Investors to Contact the Firm Regarding Their Rights Before April 21st - GlobeNewsWire
- 13 days ago - Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 26 days ago - Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session - Business Wire
- 4 weeks ago - Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer - Reuters
- 4 weeks ago - FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 4 weeks ago - Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately - PRNewsWire